Compare Mesoblast Limited (MESO) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs VF Corp — how do they compare? Mesoblast Limited trades at $14.3 (market cap $1.75B), while VF Corp trades at $14.95 (market cap $5.71B). The key difference: VF Corp is far larger — about 3.3× Mesoblast Limited's market cap, and VF Corp pays a 2.48% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and VF Corp for 65 Days on average.
| MESO | VFC | |
|---|---|---|
Market Cap | $1.75B | $5.71B |
Volume | 239,027 | 8,987,330 |
Sector | Health | Consumer Cyclical |
52-Week High | $20.96 | $21.55 |
52-Week Low | $13.19 | $12.62 |
Typical Hold Time | 15 Days | 65 Days |
Enterprise Value | $1.83B | $10.00B |
Dividend Yield | — | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
VFC trades at $15.00, up 4.31% today, showing recent volatility amid mixed earnings results. The stock maintains a bullish technical signal with strong moving average support, while fundamentals reveal declining revenue from $11.8B in 2022 to $9.5B in 2025 and negative net income of -$189.72M. Analyst consensus leans Hold with a $18.33 price target, representing 22% upside potential. Recent news highlights ongoing challenges with Vans brand performance despite strength in Outdoor segments.
VFC presents a turnaround opportunity with discounted valuation (P/S 0.61) but faces execution risks from brand-specific weaknesses. The company's deleveraging progress and dividend cut signal financial discipline, though sustained revenue growth remains critical for recovery. Near-term catalysts include Q3 2026 earnings and continued Outdoor segment momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
